While the reduction in price target could suggest a slightly less optimistic outlook for Bristol-Myers Squibb's stock, the maintenance of a Buy rating indicates that B of A Securities still sees the company as a good investment. The impact on the stock price is likely to be neutral in the short term as the positive sentiment of the Buy rating may offset the negative sentiment from the lowered price target.